Lijenta-M 500 Tab, 1 strip
Lijenta-M 500 Tab, 1 stripDescription:Lijenta-M is a combination of linagliptin and Metformin Hydrochloride with complementary mechanism of action to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha cells in the circulation.Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.IndicationLijenta-M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.Dosage & AdministrationThe dosage of Lijenta-M should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin use.Recommended starting dose: In patients currently not treated with Metformin, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily.In patients already treated with Metformin, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily.Patients already treated with linagliptin and metformin, individual components may be switched to this combination containing the same doses of each component.ContraindicationAlthough Linagliptin undergoes minimal renal excretion, Metformin is known to be substantially excreted by the kidney. The risk of Metformin accumulation and lactic acidosis increases with the degree of renal impairment. Therefore, this combination is contraindicated in patients with renal impairment. It is also contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis) and in hypersensitivity to Linagliptin or Metformin.PrecautionIn a patient with lactic acidosis who is taking Metformin, the drug should be discontinued immediately and supportive therapy promptly instituted. There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Lijenta-M. Temporarily discontinue Lijenta-M in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Metformin may lower Vitamin B12 levels; so hematologic parameters shoud be monitored annually.Side EffectsMost common side effects are nasopharyngitis and diarrhea. Hypoglycemia is more common in patients treated with this combination and sulfonylureas.Drug InteractionCationic drugs (amiloride, digoxin, morphine, ranitidine, trimethoprim etc.): May reduce metformin elimination. P-glycoprotien/CYP3A4 inducer (i.e. rifampin): The efficacy of Lijenta-M may be reduced when administered in combination.Pregnancy & LactationPregnancy category B. There are no adequate and well-controlled studies in pregnant women with this combination or its individual component; so it should be used during pregnancy only if clearly needed. Caution should also be excercised when it is administered to a lactating mother.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.120.00/=
Lijenta-M 850 Tab, 1 strip
Lijenta-M 850 Tab, 1 stripDescription:Lijenta-M is a combination of linagliptin and Metformin Hydrochloride with complementary mechanism of action to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha cells in the circulation.Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.IndicationLijenta-M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.Dosage & AdministrationThe dosage of Lijenta-M should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin use.Recommended starting dose: In patients currently not treated with Metformin, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily.In patients already treated with Metformin, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily.Patients already treated with linagliptin and metformin, individual components may be switched to this combination containing the same doses of each component.ContraindicationAlthough Linagliptin undergoes minimal renal excretion, Metformin is known to be substantially excreted by the kidney. The risk of Metformin accumulation and lactic acidosis increases with the degree of renal impairment. Therefore, this combination is contraindicated in patients with renal impairment. It is also contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis) and in hypersensitivity to Linagliptin or Metformin.PrecautionIn a patient with lactic acidosis who is taking Metformin, the drug should be discontinued immediately and supportive therapy promptly instituted. There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Lijenta-M. Temporarily discontinue Lijenta-M in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Metformin may lower Vitamin B12 levels; so hematologic parameters shoud be monitored annually.Side EffectsMost common side effects are nasopharyngitis and diarrhea. Hypoglycemia is more common in patients treated with this combination and sulfonylureas.Drug InteractionCationic drugs (amiloride, digoxin, morphine, ranitidine, trimethoprim etc.): May reduce metformin elimination. P-glycoprotien/CYP3A4 inducer (i.e. rifampin): The efficacy of Lijenta-M may be reduced when administered in combination.Pregnancy & LactationPregnancy category B. There are no adequate and well-controlled studies in pregnant women with this combination or its individual component; so it should be used during pregnancy only if clearly needed. Caution should also be excercised when it is administered to a lactating mother.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...
Tk.112.00/=
Linatab 5mg Tab
Linatab 5mg TabDescriptionLinagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1(GLP-1) and glucose-dependent Insulinotropic polypeptide (GIP), are released by the intestine throughout the day and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase Insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production.IndicationsLinagliptin is indicated in the treatment of type-2 diabetes mellitus to improve glycaemic control in adults:As monotherapy:● in patients inadequately controlled by diet and exercise alone and for whom Metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.As combination therapy:● in combination with Metformin when diet and exercise plus Metformin alone do not provide adequate glycaemic control.● in combination with a Sulphonylurea and Metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.● in combination with Insulin with or without Metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.Dosage & Administration● The recommended dose of Linagliptin is 5 mg once daily.● Linagliptin can be taken with or without food at any time of the day. If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.● For patients with renal insufficiency no dosage adjustment is required● Pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment● When Linagliptin is added to Metformin, the dose of Metformin should be maintained, and Linagliptin administered concomitantly.● When Linagliptin is used in combination with a Sulphonylurea or with Insulin, a lower dose of the Sulphonylurea or Insulin, may be considered to reduce the risk of hypoglycaemia.Side EffectsThe most common side effects of Linagliptin are stuffy or runny nose and sore throat. Hypoglycemia may occur when Linagliptin is combined with Insulin or Sulfonylurea and Metformin. Allergic reaction and musle pain also may occur.Pancreatitis, angioedema (frequency rare) and urticaria (frequency rare) were identified as additional adverse reactions.PrecautionsGeneral:Linagliptin should not be used in patients with type-1 diabetes or for the treatment of diabetic ketoacidosis.Hypoglycaemia:Linagliptin alone showed a comparable incidence of hypoglycaemia to placebo.Caution is advised when Linagliptin is used in combination with a Sulphonylurea and/or Insulin. A dose reduction of the Sulphonylurea or Insulin, may be considered.Pancreatitis:In post-marketing experience of Linagliptin there have been spontaneously reported adverse reactions of acute pancreatitis. Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain. Resolution of pancreatitis has been observed after discontinuation of Linagliptin. If pancreatitis is suspected, Linagliptin should be discontinued.Use in Pregnancy & LactationPregnanacy:The use of Linagliptin has not been studied in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Linagliptin during pregnancy.Nursing mothers:Available pharmacokinetic data in animals have shown excretion of Linagliptin/metabolites in milk. A risk to the breast-feed child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Linagliptin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.Pediatric Use:The safety and efficacy of Linagliptin in children and adolescents has not yet been established. No data are available.Geriatric Use:No dose adjustment is necessary based on age.However, clinical experience in patients > 80 years of age is limited and caution should be exercised when treating this population.Drug InteractionThe efficacy of Linagliptin may be reduced when the drug is coadministered with a strong CYP3A4 or P-glycoprotein inducer (e.g., rifampin). Therefore, the use of alternative treatments is strongly recommended. Sulfonylureas should be used with caution during treatment with Linagliptin. The pharmacokinetic characteristics of Linagliptin were not altered by the concomitant administration of Simvastatin, Digoxin, Glyburide, Warfarin, Metformi..
Tk.18.00/=
Linatab M 2.5/1000 Tab
Linatab M 2.5/1000 TabDescriptionLINATAB M is a combination of 2 oral antihyperglycemic drugs with complimentary mechanism of action to improve glycemic control in patients with type-2 diabetes mellitus: Linagliptin, a Dipeptidyl Peptidase-4 (DPP-4) inhibitor and Metformin, a member of the biguanide class.Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the inactivation of incretin hormones. Incretin hormone levels are increased in response to a meal. When blood glucose concentrations are normal or elevated, incretin hormones increase insulin synthesis and release from pancreatic beta cells. incretin hormones also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production.Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and increases peripheral glucose uptake and utilization.IndicationsIndication:Linagliptin + Metformin combination tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin is appropriate.Important Limitations of Use:- Not for treatment of type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings.- Has not been studied in patients with a history of pancreatitis.Dosage & AdministrationThe dosage of Linagliptin + Metformin combination should be individualized on the basis of both effectiveness and tolerability.Dose escalation should be gradual to reduce the gastrointestinal side effects asoociated with Metformin use.The maximum recommended dose is 2.5 mg Linagliptin/1000 mg Metformin twice daily.Should be given twice daily with meals.Recommended starting dose:- In patients currently not treated with Metformin, initiate treatment with 2.5 mg Linagliptin/500 mg Metformin hydrochloride twice daily- In patients already treated with Metformin, start with 2.5 mg Linagliptin and the current dose of Metformin taken at each of the two daily meals(e.g., a patient on Metformin 1000 mg twice daily would be started on 2.5 mg Linagliptin/1000 mg Metformin hydrochloride twice daily with meals).- Patients already treated with Linagliptin and Metformin individual components may be switched to Linagliptin + Metformin combination containing the same doses of each component.Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin:When Linagliptin + Metformin combination is used in combination with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia.Side Effects- Adverse reactions reported in 5% of patients treated with Linagliptin + Metformin combination more commonly than in patients treated with placebo are nasopharyngitis and diarrhea- Hypoglycemia was more commonly reported in patients treated with the combination of Linagliptin + Metformin along with SU compared with those treated with the combination of SU and MetforminPrecautions- Lactic acidosis can occur due to Metformin accumulation during treatment with Linagliptin + Metformin combination and is fatal in approximately 50% of cases- Patients should be cautioned against excessive alcohol intake when taking Linagliptin + Metformin combination since alcohol potentiates the effects of Metformin on lactate metabolism- It is not recommended in hepatic impairment or hypoxic states- Contraindicated in renal impairment. Because risk of metformin accumulation and lactic acidosis increases with the degree of renal impairment. Ensure normal renal function before initiating and at least annually thereafter.- There have been postmarketing reports of acute pancreatitis, including fatal pancreatitis. If pancreatitis is suspected, promptly discontinue this drug- Temporarily discontinue this drug in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids- Hypoglycemia: When used with an insulin secretagogue (e.g., sulfonylurea (SU) or insulin, consider lowering the dose of the insulin secretagogue or insulin to reduce the risk of hypoglycemia- Vitamin B12 deficiency: Metformin may lower vitamin B12 levels. Monitor hematologic parameters annually.- Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for severe joint pain and discontinue drug if appropriate.Use in Pregnancy & LactationPregnancy:Pregnancy category B.There are no adequate and well-controlled studies in pregnant women. Linagliptin + Metformin combination tablets should be used during pregnancy only if clearly needed.Nursing Mothers:Caution should be exercised when Linagliptin + Metformin combination is administered to a nursing woman.Pediatric Use:Safety and effectiveness of Linagliptin + Metfo..
Tk.15.00/=
Linatab M 2.5/850 Tab
Linatab M 2.5/850 TabDescriptionLINATAB M is a combination of 2 oral antihyperglycemic drugs with complimentary mechanism of action to improve glycemic control in patients with type-2 diabetes mellitus: Linagliptin, a Dipeptidyl Peptidase-4 (DPP-4) inhibitor and Metformin, a member of the biguanide class.Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the inactivation of incretin hormones. Incretin hormone levels are increased in response to a meal. When blood glucose concentrations are normal or elevated, incretin hormones increase insulin synthesis and release from pancreatic beta cells. incretin hormones also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production.Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and increases peripheral glucose uptake and utilization.IndicationsIndication:Linagliptin + Metformin combination tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin is appropriate.Important Limitations of Use:- Not for treatment of type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings.- Has not been studied in patients with a history of pancreatitis.Dosage & AdministrationThe dosage of Linagliptin + Metformin combination should be individualized on the basis of both effectiveness and tolerability.Dose escalation should be gradual to reduce the gastrointestinal side effects asoociated with Metformin use.The maximum recommended dose is 2.5 mg Linagliptin/1000 mg Metformin twice daily.Should be given twice daily with meals.Recommended starting dose:- In patients currently not treated with Metformin, initiate treatment with 2.5 mg Linagliptin/500 mg Metformin hydrochloride twice daily- In patients already treated with Metformin, start with 2.5 mg Linagliptin and the current dose of Metformin taken at each of the two daily meals(e.g., a patient on Metformin 1000 mg twice daily would be started on 2.5 mg Linagliptin/1000 mg Metformin hydrochloride twice daily with meals).- Patients already treated with Linagliptin and Metformin individual components may be switched to Linagliptin + Metformin combination containing the same doses of each component.Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin:When Linagliptin + Metformin combination is used in combination with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia.Side Effects- Adverse reactions reported in 5% of patients treated with Linagliptin + Metformin combination more commonly than in patients treated with placebo are nasopharyngitis and diarrhea- Hypoglycemia was more commonly reported in patients treated with the combination of Linagliptin + Metformin along with SU compared with those treated with the combination of SU and MetforminPrecautions- Lactic acidosis can occur due to Metformin accumulation during treatment with Linagliptin + Metformin combination and is fatal in approximately 50% of cases- Patients should be cautioned against excessive alcohol intake when taking Linagliptin + Metformin combination since alcohol potentiates the effects of Metformin on lactate metabolism- It is not recommended in hepatic impairment or hypoxic states- Contraindicated in renal impairment. Because risk of metformin accumulation and lactic acidosis increases with the degree of renal impairment. Ensure normal renal function before initiating and at least annually thereafter.- There have been postmarketing reports of acute pancreatitis, including fatal pancreatitis. If pancreatitis is suspected, promptly discontinue this drug- Temporarily discontinue this drug in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids- Hypoglycemia: When used with an insulin secretagogue (e.g., sulfonylurea (SU) or insulin, consider lowering the dose of the insulin secretagogue or insulin to reduce the risk of hypoglycemia- Vitamin B12 deficiency: Metformin may lower vitamin B12 levels. Monitor hematologic parameters annually.- Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for severe joint pain and discontinue drug if appropriate.Use in Pregnancy & LactationPregnancy:Pregnancy category B.There are no adequate and well-controlled studies in pregnant women. Linagliptin + Metformin combination tablets should be used during pregnancy only if clearly needed.Nursing Mothers:Caution should be exercised when Linagliptin + Metformin combination is administered to a nursing woman.Pediatric Use:Safety and effectiveness of Linagliptin + Metfor..
Tk.14.00/=
Linita 5mg Tablet
Indication: LinitaTM is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitusDosage & Administration:The recommended dose of LinitaTM is one tablet once daily. No dosage adjustment is required in patients with type 2 diabetes having renal or hepatic impairment..
Tk.15.05/=
